Beth Fischer

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd, Thomas S. Lin, James T. Dalton et al. · Blood · 2006 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

Thomas S. Lin, Amy S. Ruppert, Amy J. Johnson et al. · Journal of Clinical Oncology · 2009 · 222 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson et al. · Blood · 2008 · 155 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

Charles F. Eisenbeis, Andrew J. Grainger, Beth Fischer et al. · Clinical Cancer Research · 2004 · 75 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

Miguel A. Villalona‐Calero, M. Guillaume Wientjes, Gregory A. Otterson et al. · PubMed · 2003 · 39 citations

Medicine, Oncology, Pharmacology +17